WHO grants emergency use authorization for Chinese-made Sinopharm coronavirus vaccine
The vaccine had a 79 percent efficacy rate in stopping symptomatic covid-19 in adults between 18 and 59 years of age, the report found — lower than some high-performing U.S.-backed vaccines, including those produced by Pfizer-BioNTech and Moderna, but in the same range as AstraZeneca, another Western vaccine.
Source: WP
